EUVIMEDEUVIMED entdecken
Leserbrief

When Does Maintenance Efficacy End and Withdrawal Relapse Begin? Interpreting the QUASAR East Asian Subgroup Data

Huan Deng, Yue Peng iD

Journal of Gastroenterology and Hepatology · 2026-06 · 41 (6) · 1940-1941

DOI: 10.1111/jgh.70418 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 06.05.2026. Verfasst von Huan Deng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesia, the Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, China. Die Arbeit nennt 6 Literaturangaben. Gefördert von: General Project of Public Health Research in Shenzhen Futian District.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent subgroup analysis of the QUASAR program evaluating guselkumab in East Asian patients with moderate- to-severe ulcerative colitis provides valuable efficacy and safety data in this understudied population [1]. We offer a brief methodological note on the interpretation of the maintenance phase results. The QUASAR maintenance study used a standard randomized withdrawal design: All placebo-assigned participants had responded to intravenous guselkumab induction before being rerandomized to subcutaneous placebo. Although this design is methodologically sound [2], it complicates distinguishing the sustained benefit of continued guselkumab from disease relapse following treatment withdrawal. In the East Asian subgroup, Week 44 clinical remission was 46.3% with subcutaneous guselkumab 200 mg every 4 weeks, compared with 13.3% in the placebo withdrawal arm [3]. This large difference likely reflects both the durable efficacy of continued guselkumab and the inherent relapse risk following induction therapy withdrawal. Similar withdrawal-related relapse has been well documented in ulcerative colitis [4]. For example, azathioprine withdrawal increases 1-year relapse risk by approximately 23 percentage points, and ozanimod withdrawal results in a similar rise in relapse at Week 42. These observations confirm that treatment withdrawal substantially contributes to efficacy differences in maintenance trials [5]. The East Asian QUASAR data strongly support continued guselkumab

Autor:innen und Institutionen

  • Department of Anesthesia, the Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.

ORCID-Profile: Yue Peng

Förderung

  • General Project of Public Health Research in Shenzhen Futian District

Zitieren

APA

Deng, H., & Peng, Y. (2026). When Does Maintenance Efficacy End and Withdrawal Relapse Begin? Interpreting the QUASAR East Asian Subgroup Data. Journal of Gastroenterology and Hepatology, 41(6), 1940-1941. https://doi.org/10.1111/jgh.70418

Vancouver

Deng H, Peng Y. When Does Maintenance Efficacy End and Withdrawal Relapse Begin? Interpreting the QUASAR East Asian Subgroup Data. Journal of Gastroenterology and Hepatology. 2026;41(6):1940-1941. doi:10.1111/jgh.70418

BibTeX
@article{Deng2026,
  author = {Deng, Huan and Peng, Yue},
  title = {When Does Maintenance Efficacy End and Withdrawal Relapse Begin? Interpreting the QUASAR East Asian Subgroup Data},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  volume = {41},
  number = {6},
  pages = {1940--1941},
  doi = {10.1111/jgh.70418}
}
Kostenlos starten →